These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

274 related items for PubMed ID: 10088943

  • 21. Plasma levels of tumour necrosis factor and its soluble receptors correlate with clinical features and outcome of Hodgkin's disease patients.
    Warzocha K, Bienvenu J, Ribeiro P, Moullet I, Dumontet C, Neidhardt-Berard EM, Coiffier B, Salles G.
    Br J Cancer; 1998 Jun; 77(12):2357-62. PubMed ID: 9649158
    [Abstract] [Full Text] [Related]

  • 22. [Measurement of the serum concentrations of tumor necrosis factor alpha and its soluble receptors in normal and pre-eclamptic pregnant patients].
    Núñez-González JR, Sanabria-Vera CJ, Romero-Adrián T.
    Invest Clin; 2001 Sep; 42(3):171-81. PubMed ID: 11552506
    [Abstract] [Full Text] [Related]

  • 23. Increased soluble p55 and p75 tumour necrosis factor-alpha receptors in patients with hepatitis C-associated mixed cryoglobulinaemia.
    Kaplanski G, Marin V, Maisonobe T, Sbai A, Farnarier C, Ghillani P, Thirion X, Durand JM, Harlé JR, Bongrand P, Piette JC, Cacoub P.
    Clin Exp Immunol; 2002 Jan; 127(1):123-30. PubMed ID: 11882042
    [Abstract] [Full Text] [Related]

  • 24.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 25.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 26. Increased serum concentrations of soluble tumor necrosis factor receptors p55 and p75 in early onset neonatal sepsis.
    Doellner H, Arntzen KJ, Haereid PE, Aag S, Brubakk AM, Austgulen R.
    Early Hum Dev; 1998 Oct; 52(3):251-61. PubMed ID: 9808075
    [Abstract] [Full Text] [Related]

  • 27. Urine neopterin as a parameter of disease activity in patients with systemic lupus erythematosus: comparisons with serum sIL-2R and antibodies to dsDNA, erythrocyte sedimentation rate, and plasma C3, C4, and C3 degradation products.
    Lim KL, Jones AC, Brown NS, Powell RJ.
    Ann Rheum Dis; 1993 Jun; 52(6):429-35. PubMed ID: 8323394
    [Abstract] [Full Text] [Related]

  • 28.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 29. The model of circulating immune complexes and interleukin-6 improves the prediction of disease activity in systemic lupus erythematosus.
    Thanadetsuntorn C, Ngamjanyaporn P, Setthaudom C, Hodge K, Saengpiya N, Pisitkun P.
    Sci Rep; 2018 Feb 08; 8(1):2620. PubMed ID: 29422675
    [Abstract] [Full Text] [Related]

  • 30. Elevated serum interleukin-34 level in juvenile systemic lupus erythematosus and disease activity.
    El-Banna HS, El Khouly RM, Gado SE.
    Clin Rheumatol; 2020 May 08; 39(5):1627-1632. PubMed ID: 31907692
    [Abstract] [Full Text] [Related]

  • 31.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 32.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 33.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 34. Serum Interleukin-26 Is a New Biomarker for Disease Activity Assessment in Systemic Lupus Erythematosus.
    Brilland B, Bach-Bunner M, Gomes CN, Larochette V, Foucher E, Plaisance M, Saulnier P, Costedoat-Chalumeau N, Ghillani P, Belizna C, Delneste Y, Augusto JF, Jeannin P.
    Front Immunol; 2021 May 08; 12():663192. PubMed ID: 34054830
    [Abstract] [Full Text] [Related]

  • 35. Serum tenascin-C discriminates patients with active SLE from inactive patients and healthy controls and predicts the need to escalate immunosuppressive therapy: a cohort study.
    Závada J, Uher M, Svobodová R, Olejárová M, Hušáková M, Ciferská H, Hulejová H, Tomčík M, Šenolt L, Vencovský J.
    Arthritis Res Ther; 2015 Nov 25; 17():341. PubMed ID: 26608564
    [Abstract] [Full Text] [Related]

  • 36. Regulatory T cells and their molecular markers in peripheral blood of the patients with systemic lupus erythematosus.
    Hu S, Xiao W, Kong F, Ke D, Qin R, Su M.
    J Huazhong Univ Sci Technolog Med Sci; 2008 Oct 25; 28(5):549-52. PubMed ID: 18846336
    [Abstract] [Full Text] [Related]

  • 37. Serum soluble interleukin 7 receptor is strongly associated with lupus nephritis in patients with systemic lupus erythematosus.
    Badot V, Luijten RK, van Roon JA, Depresseux G, Aydin S, Van den Eynde BJ, Houssiau FA, Lauwerys BR.
    Ann Rheum Dis; 2013 Mar 25; 72(3):453-6. PubMed ID: 23264357
    [Abstract] [Full Text] [Related]

  • 38. Serum soluble markers of immune activation and disease activity in systemic lupus erythematosus.
    Samsonov MY, Tilz GP, Egorova O, Reibnegger G, Balabanova RM, Nassonov EL, Nassonova VA, Wachter H, Fuchs D.
    Lupus; 1995 Feb 25; 4(1):29-32. PubMed ID: 7767335
    [Abstract] [Full Text] [Related]

  • 39. Efficacy and safety of infliximab in active SLE: a pilot study.
    Uppal SS, Hayat SJ, Raghupathy R.
    Lupus; 2009 Jul 25; 18(8):690-7. PubMed ID: 19502264
    [Abstract] [Full Text] [Related]

  • 40. Changes in plasma levels of interleukin-2 receptor in relation to disease exacerbations and levels of anti-dsDNA and complement in systemic lupus erythematosus.
    ter Borg EJ, Horst G, Limburg PC, Kallenberg CG.
    Clin Exp Immunol; 1990 Oct 25; 82(1):21-6. PubMed ID: 2208793
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 14.